Uros Velickovic

Uros Velickovic

Auto-generated profile, based on publicly available information

Uros Velickovic


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
UVUros Velickovic
Uros Velickovic
DSDragica Selakovic
Dragica Selakovic
NJNemanja Jovicic
Nemanja Jovicic
MMMarina Mitrović
Marina Mitrović
VJVladimir Janjic
Vladimir Janjic
GRGvozden Rosic
Gvozden Rosic
After 70 years of clinical practice with antipsychotics in the treatment of some specific serious mental disorders, much information has been accumulated considering their efficiency as a first-line evidence-based schizophrenia therapy, but also on their adverse effects within the range from minor to life-threatening issues. In this paper, we highlight motor impairment as a frequent limiting factor. Despite the diversity of side effects following antipsychotics usage, many of those who suffer share the same pathophysiological background issues, such as oxidative damage, neuroinflammation, apoptosis, and neurodegeneration (observed in the brain regions involved in motor control). The obvious need to solve these limitations is facing restraints in clinical studies due to the ethical issues. Therefore, it seems reasonable to address the importance of preclinical investigations to overcome the adverse effects of antipsychotics. For that purpose, we analyzed the antipsychotics-induced dyskinesia seen in rodent models, with a special focus on attempts to highlight the benefits of antioxidant supplementation. Our analysis has revealed that antioxidant supplementation, with various antioxidant-rich compounds, confirms the clear neuroprotective effects of the therapy of this iatrogenic dyskinesia. Given their accessibility and safety, it seems that the administration of antioxidant-rich compounds in various forms, as an adjuvant therapy, may be beneficial in patients by lowering the risk of secondary Parkinsonism. Also, it seems that the strategy for further investigations in this field of preclinical studies should be standardized and should include more antipsychotics employed in the clinical practice.

10 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
UVUros Velickovic
Uros Velickovic
DSDragica Selakovic
Dragica Selakovic
NJNemanja Jovicic
Nemanja Jovicic
MMMarina Mitrović
Marina Mitrović
VJVladimir Janjic
Vladimir Janjic
GRGvozden Rosic
Gvozden Rosic
The authors would like to make the following corrections to this published paper